Previous 10 | Next 10 |
Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to...
New research has discovered racial disparities in the provision of treatment for advanced heart failure. The research, which was supported by the National Institutes of Health, found that Black individuals received life-changing treatments almost one-half as often as their White counterpar...
Odyssey Health (OTC: ODYY) , a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Design...
New research has discovered new information about how an experimental medication reverses neural damage linked to traumatic brain injuries. This discovery lays the foundation for a drug, which could help prevent the cognitive deficit that occurs after a concussion, to be developed in the f...
Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA Since the acquisition, the company has completed IND enabling studies a...
Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. Thi...
Heart disease, which is estimated to take around 17.9 million lives annually , is among the leading causes of death across the world. This condition commonly affects people aged 20 and older across the united States, with one American suffering a heart attack every 40 seconds. In total, rou...
Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery...
Odyssey Health (OTC: ODYY) , a company focused on developing unique, life-saving medical products, today announced the formation of Odyssey Neuropharma Inc. According to the update, the wholly owned subsidiary will focus on developing drugs to treat neurological disorders. The blood-brain b...
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused o...
News, Short Squeeze, Breakout and More Instantly...
Odyssey Group International Inc Company Name:
ODYY Stock Symbol:
OTCMKTS Market:
Odyssey Group International Inc Website:
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) , formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended January 31, 2024. The ...
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE American) under which Oragenics acquire...
LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. ( OTCOB:ODYY ), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurologi...